Skip to main content
Wiley Open Access Collection logoLink to Wiley Open Access Collection
. 2026 Apr 26;41(7):1680–1689. doi: 10.1002/mds.70335

Seeing Invisible Oligomers: Rethinking α‐Synuclein Pathology Through Proximity Ligation Assay

Hiroaki Sekiya 1,✉, Nanna Møller Jensen 2,3,4,✉, Dennis W Dickson 1, Poul Henning Jensen 2,3,4
PMCID: PMC13387933  PMID: 42036389

Abstract

Parkinson's disease (PD) and multiple system atrophy are defined by α‐synuclein (αSYN)‐positive inclusions – Lewy bodies (LBs) and glial cytoplasmic inclusions – yet mounting evidence indicates that these inclusions represent only a fraction of disease‐relevant pathology. αSYN exists in dynamic conformational states, and soluble oligomeric assemblies, often undetectable by conventional immunohistochemistry, are increasingly implicated as key neurotoxic species. The αSYN proximity ligation assay (αSYN‐PLA) enables in situ detection of widespread non‐inclusion oligomeric pathology across synucleinopathies. Notably, PLA studies in LRRK2‐associated PD demonstrate abundant oligomeric αSYN even in cases lacking LBs, challenging the centrality of inclusions in defining disease. In this Perspective, we outline the principles of αSYN‐PLA, discuss antibody strategies and structural implications of detected species, review current evidence – including LB‐negative LRRK2‐PD – and consider temporal dynamics and clinical applications of PLA‐positive aggregates as biomarkers and therapeutic targets. © 2026 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.

Keywords: α‐synuclein, oligomers, non‐inclusion pathology, proximity ligation assay, Parkinson's disease, Multiple System Atrophy


Parkinson's disease (PD) is pathologically characterized by Lewy bodies (LBs) in the neuronal cytoplasm, while multiple system atrophy (MSA) is characterized by glial cytoplasmic inclusions (GCIs) in the oligodendrocyte cytoplasm. 1 , 2 These inclusions contain aggregated structures of α‐synuclein (αSYN), predominantly as insoluble, Ser129‐phosphorylated amyloid fibrils, and have served as the central pathological hallmarks of α‐synucleinopathies. However, increasing evidence suggests that visible inclusions capture only a subset of disease‐relevant αSYN assemblies.

αSYN exists in multiple conformational states (Fig. 1). An early biochemical study characterized αSYN as a natively unfolded monomer, 3 while subsequent work proposed that it may form helically folded tetramers 4 or higher‐order polymers upon membrane binding. 5 However, in‐cell nuclear magnetic resonance studies have demonstrated that αSYN remains predominantly monomeric and disordered in mammalian cells. 6 In disease, αSYN can assemble into heterogeneous soluble aggregates, commonly termed oligomers, which may represent on‐pathway intermediates en route to fibril formation or stable off‐pathway species. 7 Both oligomers and fibrils display aggregate‐specific epitopes not exposed on native polymers, but while we know that the insoluble fibrils can exist in different folding strains in brain tissue, the structures of soluble oligomers in tissue have not yet been solved. 8 A growing body of experimental work implicates these oligomeric species as particularly neurotoxic, 9 , 10 yet their detection and anatomical localization in human brain tissue has remained challenging, as conventional immunohistochemistry (IHC) is largely blind to non‐fibrillar aggregates.

FIG. 1.

FIG. 1

States of α‐synuclein (αSYN) aggregates that may be targets of αSYN‐proximity ligation assay (PLA). Normal αSYN exists as native monomers or assembled into physiological polymers (e.g., when associated with membrane surfaces). Some of these normal states can form soluble oligomers that are conformationally distinct from native states, for example, with increased beta‐sheet content and exposing epitopes present in brain tissue from synucleinopathy patients. Such oligomers exist in different states on the pathway to form insoluble amyloid strains but may also represent end‐stage off‐pathway oligomers that cannot continue into amyloids. [Color figure can be viewed at wileyonlinelibrary.com]

The application of proximity ligation assay (PLA) has begun to transform this landscape by enabling sensitive detection of closely apposed αSYN species in situ. Throughout this article, PLA‐detected species are referred to as oligomers, consistent with prevailing terminology in the field; however, PLA detects molecular proximity rather than a defined quaternary structure, and the detected assemblies may represent a broader spectrum of aggregate species. Recent PLA‐based studies have revealed a substantial burden of non‐inclusion, oligomeric αSYN pathology across α‐synucleinopathies, extending well beyond regions marked by classical inclusions. Most strikingly, these approaches have fundamentally revised our understanding of LRRK2‐associated PD. 11 , 12

Although LRRK2‐associated PD is clinically indistinguishable from idiopathic PD, a large fraction of cases lacks LBs at autopsy. PLA analyses now demonstrate that this apparent “Lewy‐negative” pathology does not reflect an absence of αSYN aggregation. Instead, LRRK2‐PD without LBs – including cases with the pathogenic mutations G2019S, I2020T, and R1441C as well as M1646T and N2081D variants – show widespread accumulation of oligomeric αSYN throughout the brain. In some cases, oligomer burden is inversely related to the presence of classical Lewy pathology, suggesting that LRRK2 mutations may bias αSYN aggregation toward early, non‐fibrillar states or impair progression to mature inclusions.

Together, these findings challenge the long‐standing reliance on inclusion bodies as the defining feature of synucleinopathies. They raise the possibility that LRRK2‐PD represents a form of α‐synucleinopathy dominated by non‐inclusion aggregates, detectable only with molecularly sensitive approaches such as PLA. More broadly, they prompt a reassessment of how αSYN pathology is defined, staged, and targeted in both genetic and idiopathic disease. In this Perspective, we discuss the principles and current applications of αSYN‐PLA and consider how emerging PLA findings reshape concepts of αSYN aggregation and neurodegeneration.

Basic Principles of αSYN‐PLA

PLA was originally developed to detect protein–protein interactions. 13 , 14 The technique employs two antibodies, each conjugated with distinct oligonucleotide sequences, targeting proteins of interest. When these proteins are in close proximity (<40 nm), these antibodies can bind close enough to ligate the conjugated oligonucleotides. The ligation product serves as a template for amplification, and the amplified products are hybridized with complementary oligonucleotides labeled with either fluorophores or horseradish peroxidase. Fluorescent labels enable direct visualization under fluorescence microscopy, while horseradish peroxidase labels generate signals through substrate reaction as in conventional IHC staining. This approach leverages (i) the specificity of antibody–antigen recognition, (ii) the proximity of the antigens and hence the two antibodies, and (iii) high sensitivity through in situ amplification of signals.

Adaptation of PLA has enabled the detection of αSYN oligomers, early‐stage aggregates of the protein (Fig. 2). 15 , 16 In this application, identical antibodies against αSYN are each conjugated with one of two distinct oligonucleotide sequences and applied to tissue sections. Ideally, the selected antibody should be epitope‐blocking, ensuring that only one antibody can bind per αSYN molecule. As such, only when αSYN aggregates are present do these antibodies bind in close proximity, allowing subsequent ligation, amplification, and detection reactions to proceed. This enables highly sensitive and specific detection and visualization of αSYN oligomers, which are not detectable by IHC, and – to some degree – LB‐type aggregates. 11 , 12 , 15 , 17 , 18

FIG. 2.

FIG. 2

Mechanism of α‐synuclein proximity ligation assay (αSYN‐PLA). Anti‐αSYN antibodies conjugated to complementary oligonucleotides (3'‐PLUS and 5'‐MINUS probes) bind to neighboring αSYN molecules. When the probes are in close proximity (<40 nm), a linear connector oligonucleotide hybridizes to both probes and is circularized by enzymatic ligation. The resulting circular DNA template remains tethered to the proximity probes, and one probe serves as a primer for rolling circle amplification (RCA), generating a concatemeric product. The RCA product is visualized using fluorophores or horseradish peroxidase (HRP)‐labeled detection oligonucleotides that hybridize to the product, generating a visible signal upon substrate reaction. Modified from Seyika et al. 2 [Color figure can be viewed at wileyonlinelibrary.com]

Two commercial PLA kits are available for αSYN‐PLA: Duolink (Sigma‐Aldrich) and Naveni (Navinci). The latter employs UnFold PLA technology, in which all elements required for DNA circularization are incorporated within the antibody‐conjugated probes, offering improved signal efficiency at lower probe concentrations. 19

Different Antibody Combinations in αSYN‐PLA

To date, a number of different PLAs targeting αSYN have been published, including assays targeting aggregated forms of αSYN, post‐translational modifications, and interactions with other proteins. 20 , 21 , 22 , 23 As this article is mainly focused on αSYN aggregate‐targeting PLAs (Table 1), we will only briefly touch upon the other types.

TABLE 1.

Overview of currently published α‐synuclein proximity ligation assays

αSYN‐PLA variant syn211 PLA MJF‐14 PLA S3062 PLA
Antibody target/epitope

Total human αSYN (monoclonal)

aa121–125

Aggregated αSYN (monoclonal)

aa137–140

Total αSYN (polyclonal)

Approx. aa111–132

αSYN structures detected

Primarily αSYN non‐inclusion aggregates (oligomers)

Some detection of aggregates in pale bodies and LBs

Both non‐inclusion aggregates (oligomers) and inclusions/LBs (Navinci‐variant)

Only non‐inclusion aggregates (Duolink‐variant)

Not characterized
Characterization and validation in vitro

Cell model with bimolecular fluorescence complementation

Cell model with rapamycin‐induced αSYN interaction

Immobilized in vitro fibrils, oligomers, and monomers

Cell model with αSYN‐overexpression‐induced aggregation

PLA signal lowered by treatment with aggregate inhibitor

None
Advantages

Used in most studies so far

Robust detection of pathology in PD and MSA brains with low signal in controls

Correlation with symptoms (cognitive impairment, visual hallucinations)

Highly sensitive aggregate‐targeting antibody

Robust detection of pathology in PD brains with low signal in controls

PD cases show higher levels of PLA in skin biopsies than controls

Correlation with symptoms (cognitive impairment predicted by PLA in skin)

Limitations Only detects human αSYN (i.e., may overlook pathology in rodent models) Cross‐reacts with β‐synuclein in rodents (unsuitable for use in rodent models)

Potential issues from using a polyclonal antibody (not epitope‐blocking)

Little to no validation or characterization of αSYN target(s)

Abbreviations: αSYN, α‐synuclein; PLA, proximity ligation assay; aa, amino acid; LB, Lewy body; PD Parkinson's disease; MSA, multiple system atrophy.

To visualize early aggregates of α‐synuclein, αSYN‐PLA using the syn211 antibody was first developed by Roberts et al. 15 This antibody is a mouse monoclonal antibody that recognizes amino acid residues 121–125 of human αSYN, with the Asp‐Asn sequence at positions 121–122 being particularly critical for binding. 24 A key property of this antibody is that only one syn211 antibody can bind to a single αSYN molecule due to epitope occupancy, 25 preventing PLA signal generation in monomeric αSYN, where only one syn211 antibody can bind. In contrast, oligomeric forms of αSYN contain multiple molecules in close proximity, each of which can bind a syn211 antibody, thereby enabling the PLA reaction to proceed.

The specificity of syn211 αSYN‐PLA for oligomer detection has been validated through multiple complementary approaches. 15 Using two independent systems, αSYN‐PLA signals were shown to co‐localize with oligomers visualized by bimolecular fluorescence complementation and with rapamycin‐induced dimerization in a FKBP‐FRB system. Additionally, when applied to synthesized αSYN preparations in different aggregation states, syn211 PLA preferentially detected oligomeric forms over monomers or fibrils. Furthermore, biochemical validation was performed, with Western blot analyses demonstrating higher molecular weight bands corresponding to oligomeric species in tissues positive for αSYN‐PLA signals. 15 , 26 The most compelling evidence, however, stems from human brain tissue, where syn211 PLA showed minimal signal in normal controls, confirming its selectivity for pathological aggregates. 15 , 17 , 26 In PD brains, syn211 PLA detected early‐stage lesions such as oligomers and pale bodies that precede LB formation. This approach enabled visualization of early αSYN pathology that was previously undetectable by conventional IHC.

More recently, αSYN‐PLA using MJFR‐14‐6‐4‐2 (hereafter MJF‐14), a conformation‐specific antibody that selectively recognizes aggregated αSYN, has been reported. 18 MJF‐14 is a rabbit monoclonal antibody that demonstrates preferential binding to aggregated forms of αSYN over monomeric forms. The antibody recognizes the ultimate C‐terminal of αSYN (amino acid residues 137–140), which is partially masked in monomeric αSYN and explains substantially enhanced immunoreactivity of MJF‐14 toward oligomeric and fibrillar αSYN species. 27 The aggregation‐dependent specificity of MJF‐14 PLA was directly demonstrated using αSYN‐overexpressing cell models, 18 where treatment with the aggregation inhibitor ASI1D abolished MJF‐14 PLA signals, confirming that aggregation is required for signal generation.

In human brain tissue, MJF‐14 PLA showed minimal signal in normal controls while revealing extensive pathology in PD and dementia with Lewy bodies (DLB) brains. 18 An important technical consideration is that detection patterns varied depending on the PLA kit manufacturer: Duolink MJF‐14 PLA showed high specificity for early pathology with minimal LB labeling, whereas Navinci MJF‐14 PLA detected both early oligomeric pathology and LB inclusions. 18 This difference likely reflects variations in oligonucleotide linker composition between kits. Thus, this raises the possibility that modification of oligonucleotide linkers can be used as a strategy to modify the targets detected not only in the MJF‐14 PLA but more broadly in αSYN‐PLA applications. A notable limitation is that MJF‐14 antibody shows cross‐reactivity with β‐synuclein in mouse tissue, precluding its use in mouse models. 18

In addition to the syn211 and MJF‐14 PLAs, another αSYN‐PLA using the polyclonal antibody S3062 has been used in skin biopsy studies, demonstrating increased PLA signal in autonomic nerve fibers of PD patients compared with controls. 28 , 29 A subsequent study reported that higher baseline PLA signal in skin biopsies was associated with greater risk of cognitive decline, indicating possible prognostic value. 30 However, no detailed characterization of the S3062 PLA to validate the αSYN species detected has been performed in either in vitro models or post‐mortem human brain. The S3062 is a polyclonal antibody directed against a C‐terminal linear epitope of αSYN and is not intrinsically conformation‐specific, meaning that oligomer detection relies on the PLA design rather than selective binding to pathological species. As a polyclonal reagent, ensuring its specificity toward aggregated rather than monomeric αSYN species may be problematic, which can limit interpretability of the PLA signal. Additionally, polyclonal antibodies are more likely to be subject to batch variability and potential cross‐reactivity, which may impact broader application of this PLA.

While the PLAs described above target aggregated forms of αSYN, an alternative approach targets post‐translational modifications, such as the Ser129‐phosphorylation characteristic of LBs and GCIs. 31 , 32 However, conventional IHC with these antibodies has been challenged by cross‐reactivity with other proteins. To address this limitation, another PLA method using MJF‐R13 (a pSer129‐specific antibody) in combination with syn‐1 (a pan‐αSYN antibody) was reported. 33 This approach enabled specific detection of physiological pSer129‐αSYN in mouse and human brains by requiring both phosphorylation and αSYN presence, but it failed to detect LBs in DLB brains, likely due to epitope masking within dense aggregates. 33 Therefore, pSer129 PLA is suited for studying physiological pSer129‐αSYN rather than pathological inclusions.

Lastly, several studies have used PLA to detect interactions between αSYN and other neuronal proteins, including synaptic and endoplasmic reticulum proteins. 20 , 21 , 22 , 23 Though some of these interactions appear to be enriched in PD and DLB, other interactions may be purely physiological.

In summary, different antibody combinations in αSYN‐PLA enable detection of distinct αSYN species: syn211 and MJF‐14 PLAs detect aggregated forms, while native pS129 PLA detects phosphorylated species. Each approach has specific advantages and limitations, and the choice of antibody combination should be guided by the research question. Future development of αSYN‐PLA may benefit from novel antibody combinations targeting other post‐translational modifications or specific aggregate conformations. Regardless of the specific PLA setup, detailed characterization and careful validation of PLAs are crucial to ensure relevant and interpretable results.

Current Evidence from αSYN‐PLA Studies

Application of αSYN‐PLA to human post‐mortem brain has revealed pathological features not captured by conventional IHC. Multiple studies using both syn211 and MJF‐14 PLA demonstrate a dissociation between αSYN oligomers and classical Lewy pathology. In sporadic PD, oligomers are widely distributed in the cortex, including in cases without cortical LBs, whereas Lewy pathology shows a brainstem‐predominant pattern – suggesting distinct temporal dynamics, with oligomers preceding mature inclusions. 15 , 17 , 18 In LRRK2‐PD, oligomers are consistently detected regardless of LB status and may be more abundant in cases lacking LBs, supporting oligomer accumulation as a unifying pathology. 11 , 12 In MSA, abundant neuronal oligomers are observed in cortex and cerebellum, while early‐affected regions show fewer oligomers, again consistent with a temporal shift from oligomers to inclusions. 26 These findings challenge the traditional view that GCIs in oligodendrocytes represent the primary pathological substrate of MSA and suggest that neuronal involvement may play a more central role in disease pathogenesis than previously recognized.

Regional oligomer burden also correlates with clinical features. In PD and MSA, greater hippocampal oligomer load associates with memory impairment or dementia, independent of Lewy pathology. 17 , 34 In DLB, higher hippocampal oligomers correlate with faster cognitive decline and phosphorylated tau levels, while increased parahippocampal oligomers associate with visual hallucinations. 35 , 36 Interestingly, the strong correlation between oligomers and phosphorylated tau in the rapid decline group suggests potential synergistic contributions of both pathologies to the rate of cognitive decline.

Animal studies parallel these findings. In A30P human αSYN transgenic mice, syn211 PLA detects αSYN oligomers that appear early, preceding inclusion formation and progressively acquiring proteinase K resistance with aging, consistent with aggregate maturation. 37 In an MSA model with oligodendrocyte‐specific expression of human αSYN (Plp‐CreER–driven), hippocampal oligomer accumulation is accompanied by memory impairment. 34 Additionally, intranasal trehalose reduces oligomer burden and ameliorates cognitive deficits, possibly by promoting conversion to less toxic aggregated species. 38 In a complementary Tet‐Off A53T oligodendroglial model (Plp1‐tTA::tetO‐SNCA*A53T), oligomers spread from oligodendrocytes to neurons, and treatment with the connexin inhibitor INI‐0602 improves disease outcomes, potentially by facilitating interglial oligomer redistribution and reducing neuronal stress. 39 , 40 Together, though only the transgene‐driven human αSYN pathology is detected by the syn211 PLA, these models support early oligomer formation, intercellular propagation, and therapeutic responsiveness as key features of αSYN oligomer pathology.

Structure of the Target Detected by αSYN‐PLA

A key strength of αSYN‐PLA is its ability to detect smaller and less organized αSYN species than those typically visualized by conventional αSYN IHC. Defining the precise molecular species recognized by αSYN‐PLA now represents an important research priority. Although the assay is frequently described as detecting oligomers – based largely on work by Roberts et al., who demonstrated preferential recognition of oligomeric αSYN using the syn211 αSYN‐PLA – this conclusion was derived from experiments using in vitro‐generated monomers, oligomers, and fibrils immobilized on coverslips. 15 To which degree these preparations faithfully model the spectrum of aggregates present in human brain remains an open question.

Human brain tissue likely contains a continuum of intermediate aggregate species, including oligomers of varying size and β‐sheet content, protofibrils, and potentially distinct αSYN strains. Determining how these structural and conformational differences influence αSYN‐PLA detection will be critical. Notably, the original study also reported robust labeling of cortical LBs (primarily fibrillar αSYN) and of rapamycin‐induced αSYN fusion protein interactions, findings that suggest the assay may recognize a broader range of αSYN assemblies than oligomers alone. 15

Thus, while αSYN‐PLA detects oligomeric species, clarifying the boundaries of detection – both in terms of aggregate size and structural organization – remains an important objective. Moreover, different antibody combinations and even different commercial PLA platforms may influence target selectivity. This is exemplified by the MJF‐14 PLA, where Navinci kits detect both inclusion‐associated aggregates (LBs and Lewy neurites) and diffuse non‐inclusion pathology, whereas Duolink kits (Sigma) primarily detect non‐inclusion aggregates. 18 Systematic comparisons of antibody configurations and assay platforms will therefore be essential for standardization and interpretation across studies.

Progress in defining the αSYN species detected in human brain has been constrained by the limited availability of complementary methods capable of reliably distinguishing aggregate subtypes in situ. Nevertheless, several observations provide useful starting points. Proteinase K (PK) digestion studies indicate that syn211 PLA‐detected species exhibit intermediate PK sensitivity, 15 , 26 consistent with low‐β‐sheet oligomeric assemblies. In parallel, staining patterns obtained with MJF‐14 PLA resemble those observed using PK paraffin‐embedded tissue blots, which reveal widespread presynaptic αSYN aggregates not organized into inclusions. 41 , 42 Although the aggregates detected by these PK‐based approaches may represent species with relatively higher β‐sheet content, such parallels highlight the value of integrating orthogonal methodologies to refine molecular interpretation.

Looking ahead, combining αSYN‐PLA with αSYN seed amplification assays (SAA) offers a promising avenue for biological validation. SAA detects seeding‐competent aggregates and has demonstrated positivity in brain regions lacking overt Lewy pathology, suggesting the presence of smaller or less organized assemblies causing SAA‐positivity in these regions. 43 This raises the possibility of partial overlap between species detected by αSYN‐PLA and SAA, though no studies comparing αSYN‐PLA and SAA directly have been published to date. αSYN‐PLA‐positive assemblies and SAA‐detectable species are likely best conceptualized as partially overlapping but operationally distinct populations, reflecting structural proximity and functional seeding competence, respectively. αSYN‐PLA reports the nanoscale co‐localization of αSYN molecules, and thus likely captures a spectrum of oligomeric and early aggregated states, including assemblies that may not yet possess templating activity. In contrast, SAA selectively amplifies species capable of inducing conformational conversion, implying a requirement for specific β‐sheet‐rich, seeding‐competent structures. These differences suggest several non‐mutually exclusive scenarios: (i) PLA‐positive/SAA‐negative species representing early or off‐pathway oligomers; (ii) PLA‐positive/SAA‐positive assemblies corresponding to intermediates that have acquired seeding competence; and (iii) SAA‐positive/PLA‐low species reflecting low‐abundant highly active seeds or conformations with limited epitope accessibility. Temporally, this framework is consistent with a progression from PLA‐detectable assemblies to a seeding‐competent subset, though epitope exposure and antibody specificity may affect detectability of mature aggregates. Region‐matched studies integrating PLA signal intensity with SAA seeding kinetics will be essential to clarify this relationship.

At present, the most robust conclusion is that αSYN‐PLA detects diffuse, non‐inclusion αSYN aggregates and, depending on assay configuration, may also label more organized inclusions. Elucidating the precise structural identity and pathogenic significance of these species represents a key challenge and an important direction for future research.

Emergence and Temporal Dynamics of αSYN‐PLA‐Detected Species

Another key question concerns the natural history of αSYN‐PLA‐positive species, that is, how and when these assemblies arise. Empirically, αSYN‐PLA‐positive species are most abundant in α‐synucleinopathies but are also detectable in a subset of controls with no clinical diagnosis or neuropathological evidence of neurodegenerative disease. Naturally, such findings should lead to caution in interpretation of disease relevance.

Several data‐supported observations provide context to understand the phenomenon of αSYN‐PLA in controls. First, PLA‐positive αSYN species can be detected prior to overt Lewy‐related pathology, 17 , 18 consistent with in vitro aggregation kinetics studies. 44 , 45 Second, LBs themselves are occasionally observed in clinically normal individuals (incidental LB disease), 46 , 47 , 48 , 49 and related assays such as αSYN‐SAA similarly detect seeding‐competent species in some controls. 50 Together, these findings indicate that the presence of aggregated αSYN is not strictly synonymous with clinical disease.

Multiple, not mutually exclusive interpretations may explain αSYN‐PLA positivity in controls. One possibility is that some control cases represent prodromal or preclinical disease stages before the onset of obvious symptoms and LB formation. Alternatively, αSYN aggregation may reflect a dynamic equilibrium between production and clearance, with disease emerging only when this balance is perturbed. 51 This concept also fits well with many of the risk genes for development of PD, which affect either αSYN load or aggregation tendency (mutations and multiplications of the SNCA gene) or degradative systems in the cell (mutations in, e.g., GBA, LRRK2, or VPS35). 52 , 53 , 54 Another possibility is that PLA detects a heterogeneous pool of aggregates, including species that differ in pathogenic potential (e.g., on‐ and off‐pathway oligomers) or subcellular localization. 7 Supporting this, recent studies report comparable total oligomer levels in patients and controls but disease‐specific oligomer subpopulations or size distributions. 55 , 56

Overall, while αSYN‐PLA reveals a broader landscape of αSYN aggregation compared with conventional IHC, the nature, development, and biological significance of PLA‐positive assemblies remain to be fully elucidated.

LB‐Negative LRRK2 ‐PD Shows αSYN Aggregation is Not All LBs

The recent αSYN‐PLA studies showing substantial accumulation of PLA‐positive αSYN aggregates not organized into inclusions in LRRK2 cases illustrate the power of αSYN‐PLA: it is not only a tool that can visualize αSYN aggregates that precede the conventional Lewy pathology, but it also reveals distinct subtypes of PD with αSYN aggregation but no formation of Lewy inclusions. Importantly, this shows that the absence of LBs in these LB‐negative LRRK2 cases is not due to a lack of αSYN aggregation, as has previously been speculated. 57 , 58

Instead, the lack of LBs in some cases with LRRK2‐mutations suggests a likely perturbation of the inclusion formation and thus indicates that LB formation is not an automatic process but instead a regulated cellular response to the aggregate formation. Though our understanding of the process of LB formation is very limited – likely because αSYN aggregation has long been considered synonymous with LB formation and thus not studied as separate processes – there are some indications of potentially relevant players. First, it has been proposed that the LB may be a type of aggresome – a structure created from the centrosome to sequester and degrade abnormal and potentially toxic proteins, which cannot otherwise be cleared. 59 The suggestion is made based on the similarities in localization as well as protein composition and distribution in the LBs and aggresomes, including presence of centrosome/aggresome markers γ‐tubulin and pericentrin in LBs. 60 However, more recent studies of LBs using correlative light and electron microscopy show mitochondria, other vesicular structures, and membranous fragments as major constituents of LBs, which may not be compatible with the aggresome hypothesis. 61 Interactions between αSYN and membranous organelles indeed appear to be a key step in the formation of LBs, based on studies in primary neurons treated with αSYN fibrils. 62

Second, though LBs are typically associated with LB diseases, they can also be found in a number of rare genetic disorders, including mitochondrial diseases, neurodegeneration with brain iron accumulation, and lysosomal storage disorders and lipidoses. 63 Seeing that the frequency of LB‐positivity in these disorders is much higher than would be expected in a matched control population, the genetic defect causing these diseases may also impact the formation of LBs. As such, relevant starting points for elucidating the exact mechanisms of LB formation include pathways associated with autophagy, lipid metabolism, and mitochondrial functions. 63 Detailed studies of the process of LB formation may also give further insight into the debate of the role of LBs and help us determine whether they are deleterious or protective in nature.

Potential Clinical Usability of αSYN‐PLA‐Positive Species as a Biomarker or Treatment Target

With the promising results achieved using αSYN‐PLAs in studies of post‐mortem human brain, demonstrating their ability to detect widespread αSYN aggregates at early stages, an obvious next step is to investigate clinical usability of αSYN‐PLA. One possibility is to assess the assay's usefulness as a diagnostic or prognostic biomarker, using peripheral tissues accessible in patients. For such tissues – especially skin biopsies – IHC studies assessing pSer129‐αSYN or other αSYN markers have already shown potential, though sensitivity and specificity measures vary substantially between studies. 64 These variations may be due to differences in the way the investigation cohorts are constructed, where we might expect differences in skin αSYN positivity between, for example, the proposed brain‐first and body‐first subtypes of PD. At present, we are only aware of one study directly comparing αSYN‐IHC in skin from brain‐ versus body‐first PD, which indeed showed higher skin αSYN positivity in body‐first cases. 65

To date, only a few studies with αSYN‐PLA in skin have been conducted, using either the syn211 or S3062 αSYN antibody, showing the compatibility of αSYN‐PLA with skin biopsies. 28 , 29 , 30 , 66 However, further studies – particularly using monoclonal αSYN antibodies – are needed to determine whether αSYN‐PLA is better than αSYN‐IHC for either diagnostic or prognostic purposes. In terms of diagnostic purposes, a potentially interesting approach could also be to modify the current αSYN‐PLAs to try to create disease‐ or strain‐specific assays, based on the findings that PLA kits from different vendors (meaning distinct linkers for the PLA probes) produce distinct staining patterns with or without detection of LBs. 18 If proved feasible, this could aid substantially in providing a firm, correct diagnosis at early stages of disease for especially the atypical parkinsonism cases, including MSA, progressive supranuclear palsy, and corticobasal degeneration.

In parallel with tissue‐based approaches, proximity‐dependent assay principles are also being adapted for biofluid‐based biomarker discovery. PLA has been applied to detect amyloid β oligomers in cerebrospinal fluid, demonstrating the feasibility of proximity‐based oligomer detection in biofluids. 67 Furthermore, the recently developed NULISA (NUcleic acid–Linked Immuno‐Sandwich Assay) platform represents a conceptually related technology to PLA, in which antibody‐bound oligonucleotides generate amplifiable DNA reporters upon target engagement, enabling highly sensitive, multiplexed protein detection using sequencing readouts. 68 Notably, a recent study using NULISA has demonstrated the ability to distinguish PD and MSA from controls based on plasma protein signatures, highlighting the translational potential of proximity‐based proteomic approaches in synucleinopathies. 69 These approaches warrant exploration of αSYN oligomer detection in biofluids as a potential biomarker strategy.

In addition to the potential usability as a biomarker, it is likely also worthwhile to investigate αSYN‐PLA‐positive aggregates as a therapeutic target in α‐synucleinopathies. Discussions about relative roles and toxicity of oligomeric versus fibrillar αSYN are still ongoing with studies showing conflicting evidence, but the more transient nature of smaller, oligomeric αSYN aggregates makes them potentially easier to degrade. The fact that they also appear to be involved at much earlier stages of disease – which would be a better timepoint to treat α‐synucleinopathies than at advanced stages dominated by substantial cell loss – only increases their attractiveness as a treatment target.

Author Roles

(1) Manuscript Preparation: A. Design, B. Writing of the First Draft, C. Review and Critique.

H.S.: 1A, 1B, 1C.

N.M.J.: 1A, 1B, 1C.

D.W.D.: 1A, 1C.

P.H.J.: 1A, 1C.

Acknowledgments

H.S. is partially supported by fellowships from the Japanese Society of Neurology, the Cell Science Research Foundation, and the Uehara Memorial Foundation, the American Parkinson Disease Association Research Grant, the Multiple System Atrophy Coalition Research Grant, the State of Florida Ed and Ethel Moore Alzheimer's Disease Research Program (24A08), and Jaye F. and Betty F. Dyer Foundation Fellowship in progressive supranuclear palsy research. N.M.J. and P.H.J. are funded by The Michael J. Fox Foundation (#MJFF‐027074), the Lundbeck Foundation (#grants R223‐2015‐4222 for P.H.J. and R248‐2016‐2518 for Danish Research Institute of Translational Neuroscience—DANDRITE, Nordic‐EMBL Partnership for Molecular Medicine, Aarhus University, Denmark), and the Danish Parkinson Association.

Relevant conflicts of interest/financial disclosures: The authors have no conflicts of interest to declare. All funding sources are listed under Acknowledgments.

Funding agency: No specific funding was obtained for this study.

Contributor Information

Hiroaki Sekiya, Email: sekiya.hiroaki@mayo.edu.

Nanna Møller Jensen, Email: nanna.mj@dandrite.au.dk.

Data Availability Statement

Data sharing not applicable to this article as no datasets were generated or analysed during the current study.

References

  • 1. Dickson DW. Parkinson's disease and parkinsonism: neuropathology. Cold Spring Harb Perspect Med 2012;2(8):a009258. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2. Sekiya H, Matsubara T, DeTure MA, Dickson DW. Neuropathology of Lewy body dementia: Lewy‐related pathology, α‐synuclein oligomers, and comorbid pathologies. Mol Neurodegener 2025;20(1):117. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3. Weinreb PH, Zhen W, Poon AW, Conway KA, Lansbury PT Jr. NACP, a protein implicated in Alzheimer's disease and learning, is natively unfolded. Biochemistry 1996;35(43):13709–13715. [DOI] [PubMed] [Google Scholar]
  • 4. Bartels T, Choi JG, Selkoe DJ. α‐Synuclein occurs physiologically as a helically folded tetramer that resists aggregation. Nature 2011;477(7362):107–110. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5. Burré J, Sharma M, Südhof TC. α‐Synuclein assembles into higher‐order multimers upon membrane binding to promote SNARE complex formation. Proc Natl Acad Sci U S A 2014;111(40):E4274–E4283. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6. Theillet FX, Binolfi A, Bekei B, et al. Structural disorder of monomeric α‐synuclein persists in mammalian cells. Nature 2016;530(7588):45–50. [DOI] [PubMed] [Google Scholar]
  • 7. Alam P, Bousset L, Melki R, Otzen DE. α‐Synuclein oligomers and fibrils: a spectrum of species, a spectrum of toxicities. J Neurochem 2019;150(5):522–534. [DOI] [PubMed] [Google Scholar]
  • 8. Scheres SHW, Ryskeldi‐Falcon B, Goedert M. Molecular pathology of neurodegenerative diseases by cryo‐EM of amyloids. Nature 2023;621(7980):701–710. [DOI] [PubMed] [Google Scholar]
  • 9. Winner B, Jappelli R, Maji SK, et al. In vivo demonstration that alpha‐synuclein oligomers are toxic. Proc Natl Acad Sci U S A 2011;108(10):4194–4199. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10. Cremades N, Cohen SI, Deas E, et al. Direct observation of the interconversion of normal and toxic forms of α‐synuclein. Cell 2012;149(5):1048–1059. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11. Sekiya H, Franke L, Hashimoto Y, et al. Widespread distribution of α‐synuclein oligomers in LRRK2‐related Parkinson's disease. Acta Neuropathol 2025;149(1):42. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12. Jensen NM, Vitic Z, Antorini MR, Viftrup TB, Parkkinen L, Jensen PH. Abundant non‐inclusion α‐synuclein pathology in Lewy body‐negative LRRK2‐mutant cases. Acta Neuropathol 2025;149(1):41. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13. Söderberg O, Gullberg M, Jarvius M, et al. Direct observation of individual endogenous protein complexes in situ by proximity ligation. Nat Methods 2006;3(12):995–1000. [DOI] [PubMed] [Google Scholar]
  • 14. Bellucci A, Fiorentini C, Zaltieri M, Missale C, Spano P. The “in situ” proximity ligation assay to probe protein‐protein interactions in intact tissues. Methods Mol Biol 2014;1174:397–405. [DOI] [PubMed] [Google Scholar]
  • 15. Roberts RF, Wade‐Martins R, Alegre‐Abarrategui J. Direct visualization of alpha‐synuclein oligomers reveals previously undetected pathology in Parkinson's disease brain. Brain 2015;138(Pt6):1642–1657. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16. Roberts RF, Bengoa‐Vergniory N, Alegre‐Abarrategui J. Alpha‐synuclein proximity ligation assay (AS‐PLA) in brain sections to probe for alpha‐synuclein oligomers. Methods Mol Biol 2019;1948:69–76. [DOI] [PubMed] [Google Scholar]
  • 17. Sekiya H, Tsuji A, Hashimoto Y, et al. Discrepancy between distribution of alpha‐synuclein oligomers and Lewy‐related pathology in Parkinson's disease. Acta Neuropathol Commun 2022;10(1):133. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18. Jensen NM, Fu Y, Betzer C, et al. MJF‐14 proximity ligation assay detects early non‐inclusion alpha‐synuclein pathology with enhanced specificity and sensitivity. NPJ Parkinsons Dis 2024;10(1):227. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19. Klaesson A, Grannas K, Ebai T, et al. Improved efficiency of in situ protein analysis by proximity ligation using UnFold probes. Sci Rep 2018;8(1):5400. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20. Longhena F, Faustini G, Varanita T, et al. Synapsin III is a key component of α‐synuclein fibrils in Lewy bodies of PD brains. Brain Pathol 2018;28(6):875–888. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21. Betzer C, Lassen LB, Olsen A, et al. Alpha‐synuclein aggregates activate calcium pump SERCA leading to calcium dysregulation. EMBO Rep 2018;19(5):e44617. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22. Almandoz‐Gil L, Persson E, Lindström V, Ingelsson M, Erlandsson A, Bergström J. In situ proximity ligation assay reveals co‐localization of alpha‐synuclein and SNARE proteins in murine primary neurons. Front Neurol 2018;9:180. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23. Longhena F, Faustini G, Missale C, Pizzi M, Bellucci A. Dopamine transporter/α‐synuclein complexes are altered in the post mortem caudate putamen of Parkinson's disease: an in situ proximity ligation assay study. Int J Mol Sci 2018;19(6):1611. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24. Giasson BI, Jakes R, Goedert M, et al. A panel of epitope‐specific antibodies detects protein domains distributed throughout human alpha‐synuclein in Lewy bodies of Parkinson's disease. J Neurosci Res 2000;59(4):528–533. [DOI] [PubMed] [Google Scholar]
  • 25. El‐Agnaf OM, Salem SA, Paleologou KE, et al. Detection of oligomeric forms of alpha‐synuclein protein in human plasma as a potential biomarker for Parkinson's disease. FASEB J 2006;20(3):419–425. [DOI] [PubMed] [Google Scholar]
  • 26. Sekiya H, Kowa H, Koga H, et al. Wide distribution of alpha‐synuclein oligomers in multiple system atrophy brain detected by proximity ligation. Acta Neuropathol 2019;137(3):455–466. [DOI] [PubMed] [Google Scholar]
  • 27. Kumar ST, Jagannath S, Francois C, Vanderstichele H, Stoops E, Lashuel HA. How specific are the conformation‐specific α‐synuclein antibodies? Characterization and validation of 16 α‐synuclein conformation‐specific antibodies using well‐characterized preparations of α‐synuclein monomers, fibrils and oligomers with distinct structures and morphology. Neurobiol Dis 2020;146:105086. [DOI] [PubMed] [Google Scholar]
  • 28. Mazzetti S, Basellini MJ, Ferri V, et al. α‐Synuclein oligomers in skin biopsy of idiopathic and monozygotic twin patients with Parkinson's disease. Brain 2020;143(3):920–931. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29. Mazzetti S, Contaldi E, Basellini MJ, et al. Comparing GBA1‐Parkinson's disease and idiopathic Parkinson's disease: α‐synuclein oligomers and synaptic density as biomarkers in the skin biopsy. Brain Pathol 2024;34(6):e13284. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30. Contaldi E, Basellini MJ, Mazzetti S, et al. α‐Synuclein oligomers in skin biopsies predict the worsening of cognitive functions in Parkinson's disease: a single‐center longitudinal cohort study. Int J Mol Sci 2024;25(22):12176. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31. Fujiwara H, Hasegawa M, Dohmae N, et al. Alpha‐synuclein is phosphorylated in synucleinopathy lesions. Nat Cell Biol 2002;4(2):160–164. [DOI] [PubMed] [Google Scholar]
  • 32. Nishie M, Mori F, Fujiwara H, et al. Accumulation of phosphorylated alpha‐synuclein in the brain and peripheral ganglia of patients with multiple system atrophy. Acta Neuropathol 2004;107(4):292–298. [DOI] [PubMed] [Google Scholar]
  • 33. Arlinghaus R, Iba M, Masliah E, Cookson MR, Landeck N. Specific detection of physiological S129 phosphorylated α‐synuclein in tissue using proximity ligation assay. J Parkinsons Dis 2023;13(2):255–270. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34. Miki Y, Tanji K, Shinnai K, et al. Pathological substrate of memory impairment in multiple system atrophy. Neuropathol Appl Neurobiol 2022;48:e12844. [DOI] [PubMed] [Google Scholar]
  • 35. Sekiya H, Franke L, Ono D, et al. Impact of hippocampal α‐synuclein oligomers on cognitive trajectory in patients with dementia with Lewy bodies. Alzheimers Dement 2025;21(8):e70374. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36. Sekiya H, Franke L, Ono D, et al. Association between visual hallucinations and α‐synuclein oligomers in patients with dementia with Lewy bodies. Alzheimers Dement 2025;21(11):e70904. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37. Behere A, Thörnqvist PO, Winberg S, Ingelsson M, Bergström J, Ekmark‐Lewén S. Visualization of early oligomeric α‐synuclein pathology and its impact on the dopaminergic system in the (Thy‐1)‐h[A30P]α‐syn transgenic mouse model. J Neurosci Res 2021;99(10):2525–2539. [DOI] [PubMed] [Google Scholar]
  • 38. Tanaka MT, Miki Y, Mori F, et al. Intranasal administration of trehalose reduces α‐synuclein oligomers and accelerates α‐synuclein aggregation. Brain Commun 2024;6(4):fcae193. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39. Harada M, Masaki K, Tanaka T, et al. Facilitated α‐synuclein oligomer sharing among glial cells by a centrally acting connexin inhibitor attenuates a rapidly progressive multiple system atrophy‐cerebellar type model by reducing the neuronal α‐synuclein burden. Acta Neuropathol Commun 2025;13(1):197. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40. Yamaguchi H, Nishimura Y, Matsuse D, et al. A rapidly progressive multiple system atrophy‐cerebellar variant model presenting marked glial reactions with inflammation and spreading of α‐synuclein oligomers and phosphorylated α‐synuclein aggregates. Brain Behav Immun 2024;121:122–141. [DOI] [PubMed] [Google Scholar]
  • 41. Neumann M, Kahle PJ, Giasson BI, et al. Misfolded proteinase K‐resistant hyperphosphorylated alpha‐synuclein in aged transgenic mice with locomotor deterioration and in human alpha‐synucleinopathies. J Clin Invest 2002;110(10):1429–1439. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42. Schulz‐Schaeffer WJ. The synaptic pathology of alpha‐synuclein aggregation in dementia with Lewy bodies, Parkinson's disease and Parkinson's disease dementia. Acta Neuropathol 2010;120(2):131–143. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43. Bentivenga GM, Mammana A, Baiardi S, et al. Performance of a seed amplification assay for misfolded alpha‐synuclein in cerebrospinal fluid and brain tissue in relation to Lewy body disease stage and pathology burden. Acta Neuropathol 2024;147(1):18. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44. Iljina M, Garcia GA, Horrocks MH, et al. Kinetic model of the aggregation of alpha‐synuclein provides insights into prion‐like spreading. Proc Natl Acad Sci U S A 2016;113(9):E1206–E1215. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45. Tofaris GK. Initiation and progression of α‐synuclein pathology in Parkinson's disease. Cell Mol Life Sci 2022;79(4):210. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46. Parkkinen L, Soininen H, Alafuzoff I. Regional distribution of alpha‐synuclein pathology in unimpaired aging and Alzheimer disease. J Neuropathol Exp Neurol 2003;62(4):363–367. [DOI] [PubMed] [Google Scholar]
  • 47. Saito Y, Ruberu NN, Sawabe M, et al. Lewy body‐related alpha‐synucleinopathy in aging. J Neuropathol Exp Neurol 2004;63(7):742–749. [DOI] [PubMed] [Google Scholar]
  • 48. Dickson DW, Fujishiro H, DelleDonne A, et al. Evidence that incidental Lewy body disease is pre‐symptomatic Parkinson's disease. Acta Neuropathol 2008;115(4):437–444. [DOI] [PubMed] [Google Scholar]
  • 49. Frigerio R, Fujishiro H, Ahn TB, et al. Incidental Lewy body disease: do some cases represent a preclinical stage of dementia with Lewy bodies? Neurobiol Aging 2011;32(5):857–863. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50. Blauwendraat C, Morris HR, Van Keuren‐Jensen K, Noyce AJ, Singleton AB. The temporal order of genetic, environmental, and pathological risk factors in Parkinson's disease: paving the way to prevention. Lancet Neurol 2025;24(11):969–975. [DOI] [PubMed] [Google Scholar]
  • 51. Cotton MW, Venkatesan S, Beckwith JS, et al. Neurodegeneration emerges at a cellular tipping point between aggregate accumulation and removal. bioRxiv [Preprint] 2025;2025.09.08.674880. 10.1101/2025.09.08.674880. [DOI] [Google Scholar]
  • 52. Devine MJ, Gwinn K, Singleton A, Hardy J. Parkinson's disease and α‐synuclein expression. Mov Disord 2011;26(12):2160–2168. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 53. Flagmeier P, Meisl G, Vendruscolo M, et al. Mutations associated with familial Parkinson's disease alter the initiation and amplification steps of α‐synuclein aggregation. Proc Natl Acad Sci U S A 2016;113(37):10328–10333. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 54. Abe T, Kuwahara T. Targeting of lysosomal pathway genes for Parkinson's disease modification: insights from cellular and animal models. Front Neurol 2021;12:681369. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 55. Andrews R, Fu B, Toomey CE, et al. Large‐scale visualization of α‐synuclein oligomers in Parkinson's disease brain tissue. Nat Biomed Eng 2025. 10.1038/s41551-025-01496-4 (Epub ahead of print). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 56. Gregersen E, Antorini MR, Reimer L, et al. Higher‐molecular‐weight a‐synuclein oligomers are increased in the brain cytosol of patients with dementia with Lewy bodies. NPJ Parkinsons Dis 2026;12:89. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 57. Schneider SA, Alcalay RN. Neuropathology of genetic synucleinopathies with parkinsonism: review of the literature. Mov Disord 2017;32(11):1504–1523. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 58. Rivero‐Ríos P, Romo‐Lozano M, Fasiczka R, Naaldijk Y, Hilfiker S. LRRK2‐related Parkinson's disease due to altered endolysosomal biology with variable Lewy body pathology: a hypothesis. Front Neurosci 2020;14:556. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 59. Olanow CW, Perl DP, GN DM, KS MN. Lewy‐body formation is an aggresome‐related process: a hypothesis. Lancet Neurol 2004;3(8):496–503. [DOI] [PubMed] [Google Scholar]
  • 60. McNaught KS, Shashidharan P, Perl DP, Jenner P, Olanow CW. Aggresome‐related biogenesis of Lewy bodies. Eur J Neurosci 2002;16(11):2136–2148. [DOI] [PubMed] [Google Scholar]
  • 61. Shahmoradian SH, Lewis AJ, Genoud C, et al. Lewy pathology in Parkinson's disease consists of crowded organelles and lipid membranes. Nat Neurosci 2019;22(7):1099–1109. [DOI] [PubMed] [Google Scholar]
  • 62. Mahul‐Mellier AL, Burtscher J, Maharjan N, et al. The process of Lewy body formation, rather than simply α‐synuclein fibrillization, is one of the major drivers of neurodegeneration. Proc Natl Acad Sci U S A 2020;117(9):4971–4982. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 63. Erskine D, Koss D, Korolchuk VI, Outeiro TF, Attems J, McKeith I. Lipids, lysosomes and mitochondria: insights into Lewy body formation from rare monogenic disorders. Acta Neuropathol 2021;141(4):511–526. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 64. Peng H, Chen S, Wu S, et al. Alpha‐synuclein in skin as a high‐quality biomarker for Parkinson's disease. J Neurol Sci 2023;451:120730. [DOI] [PubMed] [Google Scholar]
  • 65. Liu M, Wen T, Luo H, et al. Distinct cutaneous α‐synuclein signatures in body‐first and brain‐first Parkinson's disease subtypes. Brain 2025;awaf395. [DOI] [PubMed] [Google Scholar]
  • 66. Vacchi E, Senese C, Chiaro G, et al. Alpha‐synuclein oligomers and small nerve fiber pathology in skin are potential biomarkers of Parkinson's disease. NPJ Parkinsons Dis 2021;7(1):119. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 67. Kamali‐Moghaddam M, Pettersson FE, Wu D, Englund H, Darmanis S, Lord A. Sensitive detection of Aβ protofibrils by proximity ligation—relevance for Alzheimer's disease. BMC Neurosci 2010;11:124. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 68. Feng W, Beer JC, Hao Q, et al. NULISA: a proteomic liquid biopsy platform with attomolar sensitivity and high multiplexing. Nat Commun 2023;14(1):7238. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 69. Vijiaratnam N, Girges C, Mitchell A, et al. Peripheral and CSF protein quantification in Parkinson's disease and multiple system atrophy‐the nucleic acid‐linked immuno‐sandwich assay. Brain Commun 2026;8(2):fcag035. [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Data Availability Statement

Data sharing not applicable to this article as no datasets were generated or analysed during the current study.


Articles from Movement Disorders are provided here courtesy of Wiley

RESOURCES